Category:
Carcinomas
Cancer type:
Kidney
Descriptor:
Therapeutic Development
Reference Number:
340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Oncogene 23, 5387-93 (2004)
PubMed link
Reference Number:
634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
J Biol Chem.
283, 2675-83 (2008)
PubMed link
Reference Number:
686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET?
Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4
PubMed link
